Friday 6 November 2026
Export ISRG’s income statement to Excel — free account
Intuitive Surgical, Inc.
ISRG Healthcare Medical Instruments & Supplies
Intuitive Surgical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.1 billion, up 20.5% from fiscal 2024.
- Revenue
- +21.7%
- EPS
- −24.2%
- Free cash flow
- +51.0%
Quarter to September 2026, against a year earlier
465.68
16.42
−3.41%
Follow ISRG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
48.64 | 44.99 | 55.08 | 70.71 |
+8 more quarters Free account |
P/S ratio |
12.26 | 12.76 | 15.46 | 20.08 | |
P/FCF ratio |
38.94 | 43.08 | 56.80 | 81.16 | |
P/Operating CF |
115.93 | 132.72 | 179.41 | 226.48 | |
P/B ratio |
8.80 | 7.70 | 9.30 | 11.27 | |
Price to Tangible BV |
9.89 | 8.49 | 10.30 | 12.09 | |
EV/Sales |
11.91 | 12.29 | 15.03 | 19.49 | |
EV/EBITDA |
33.34 | 31.88 | 40.20 | 54.16 | |
EV/Operating CF |
33.71 | 36.59 | 47.34 | 64.74 | |
EV/FCF |
37.84 | 41.49 | 55.23 | 78.77 | |
Quick Ratio |
2.28 | 3.58 | 3.20 | 3.72 | |
Current Ratio |
3.33 | 4.96 | 4.61 | 4.87 | |
Net Debt/EBITDA |
(5.08) | (4.37) | (4.32) | (5.39) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.60 | 0.54 | 0.54 | 0.51 | |
Operating CF/Net income |
2.34 | 1.30 | 1.11 | 1.12 | |
Capex/Depreciation |
(0.55) | (0.51) | (0.30) | (0.69) | |
Research and Development Expense of Revenue |
13.39% | 12.81% | 13.06% | 12.31% | |
Selling, General and Administrative Expense of Revenue |
20.78% | 21.36% | 22.13% | 23.97% | |
Intangible Assets out of Total Assets |
0.09 | 0.08 | 0.08 | 0.06 | |
Share Based Compensation of Revenue |
6.97% | 7.26% | 7.56% | 7.09% | |
Graham Net Nets |
0.04 | 0.05 | 0.04 | 0.04 | |
Graham Number |
93.20 | 101.38 | 96.63 | 95.18 | |
Earnings Yield |
2.06% | 2.22% | 1.82% | 1.41% | |
Free Cash Flow Yield |
2.57% | 2.32% | 1.76% | 1.23% | |
Revenue per Share |
8.74 | 8.17 | 7.81 | 8.03 | |
Operating CF per Share |
3.51 | 3.00 | 2.57 | 2.50 | |
Capex per Share |
(0.32) | (0.32) | (0.16) | (0.46) | |
Free Cash Flow per Share |
3.18 | 2.68 | 2.41 | 2.05 | |
Cash per Share |
11.58 | 14.73 | 12.73 | 16.63 | |
Shareholders Equity per Share |
46.18 | 51.67 | 49.58 | 50.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
46.18 | 51.67 | 49.58 | 50.27 | |
Free Cash Flow |
1,111.00 | 948.40 | 854.60 | 730.00 | |
Working Capital |
5,895.30 | 7,619.80 | 6,898.50 | 7,773.30 | |
Capital Expenditures |
(113.10) | (112.60) | (57.30) | (162.50) | |
Net Current Asset Value |
5,197.00 | 6,963.80 | 6,295.70 | 7,262.50 | |
EV/EBIT |
41.98 | 39.29 | 49.36 | 66.61 | |
Capex to Sales |
0.04 | 0.04 | 0.02 | 0.06 | |
Price to Operating Income |
43.21 | 40.80 | 50.77 | 68.62 | |
| Other line items | |||||
Average Receivables |
1,490.50 | 1,471.20 | 1,408.55 | 1,376.35 | |
Average Payables |
285.35 | 272.00 | 304.55 | 224.25 | |
Average Inventory |
1,955.05 | 1,847.85 | 1,749.35 | 1,663.60 | |
Average Assets |
19,350.45 | 20,519.90 | 19,665.70 | 19,600.95 | |
Average Common Equity |
16,579.95 | 18,125.40 | 17,402.45 | 17,235.65 |
Columns are period end dates · fundamentals updated 2 Nov 2026